Lipids are the chemical substances that are primarily insoluble in water such as cholesterol and the triglycerides. The Hyperlipidemia is said to be a medical condition registered by an increase of lipid level in the blood circulation. The rise in lipid levels further leads to rise in fatty deposits in the arteries that lead to blockages in the arteries of the patient. The blockages in turn lead to rise in the risk associated to heart attacks. The Hyperlipidemic agents lead to decrease in cholesterol-lowering the drugs or antihyperlipidemic agents, leading to diverse group of pharmaceuticals used in the treatment of high levels of fats such as cholesterol in blood (hyperlipidemia).
According to study, “Antihyperlipidemic Drugs Market by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrates, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, and Combination): Global Opportunity Analysis and Industry Forecast, 2019-2026” the key companies operating in the global antihyperlipidemic drugs market are Boehringer Ingelheim GmbH, Johnson and Johnson, Merck KGaA, Bayer AG, Sanofi S.A., Pfizer, Inc. AstraZeneca plc., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Company, and Novartis International AG.
Based on drug class, the antihyperlipidemic drugs market is segregated into cholesterol absorption inhibitors, bile acid sequesters fibrates (fibric acid derivatives), PCSK9 inhibitors, miscellaneous antihyperlipidemic agents, and statins. The fibrate type of antihyperlipidemic drugs reduces the overall fatty acid and triglyceride levels further stimulates the peroxisomal b-oxidation pathway over the forecast period. Statins are used in lowering the cholesterol levels by interrupting the cholesterol biosynthetic pathway. In addition, based on distribution channel, market is segmented into retail stores, hospital pharmacies, and online retailers.
The Antihyperlipidemic drugs market is further supported by significant rise in incidence of disorders connected to the distributed cholesterol levels in blood, followed by increase in sedentary lifestyle and substantially rise in the awareness adding to complications related to Hyperlipidaemia. However, substantial high cost of treatment may further impact the overall market. The other factors leading to boost the overall antihyperlipidemic drugs market leading to surge in the geriatric population and further rise in healthcare expenditure across various geographies. In addition, the other factors boosting the overall growth includes some of the additional benefits being offered by statins associated to improved endothelial function, enhancing the stability of atherosclerotic plaques, reducing the overall amount of inflammation & damage to cells due to oxidative stress.
Based on geography, the North-American is a leading region in global antihyperlipidemic drugs market owing to rise in prevalence of vascular diseases and number of amputations in the region. Whereas, the European region is estimated to exhibit substantial growth rate due to compulsory medical insurance in countries such as Germany and France coupled with high research & development activities in the healthcare sector over the forecast period. The Asian-Pacific region is also estimated to exhibit to witness the substantial growth rate due to high disposable income and increase in healthcare expenditure by governments & private players during the forecast period. The global antihyperlipidemic drugs market accounted for nearly US$ 9,456 million in 2018, and is projected to reach US$ 16,864 million by 2026, with a CAGR of 7.5% from 2019-2026 forecast periods.
For More Information, click on the link below:-
Ankur Gupta, Head Marketing & Communications